Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)

Carcinogenesis

Volumn 27, Issue 5, 2006, Pages 1105-1112

  Kim, Dae J ^a,b   Sandeep Prabhu, K ^a   Gonzalez, Frank J ^c   Peters, Jeffrey M ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROSTACYCLIN; PROSTAGLANDIN E2; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOASSAY; CANCER STAGING; CELL GROWTH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN BIOPSY; SKIN CANCER; SKIN PAPILLOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CARCINOGENS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; FEMALE; KERATINOCYTES; MALE; MICE; MICE, INBRED C57BL; PPAR DELTA; PPAR-BETA; SKIN NEOPLASMS; SULINDAC;

EID: 33646181467     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi346     Document Type: Article

References (60)

1. Trifan,O.C. and Hla,T. (2003) Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J. Cell Mol. Med., 7, 207-222.
2. Pentland,A.P., Mahoney,M., Jacobs,S.C. and Holtzman,M.J. (1990) Enhanced prostaglandin synthesis after ultraviolet injury is mediated by endogenous histamine stimulation. A mechanism for irradiation erythema. J. Clin. invest., 86, 566-574.
3. Tsuboi,K., Sugimoto,Y. and Ichikawa,A. (2002) Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat., 68-69, 535-556.
4. Gupta,R.A. and Dubois,R.N. (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer, 1, 11-21.
5. Muller-Decker,K., Neufang,G., Berger,I., Neumann,M., Marks,F. and Furstenberger,G. (2002) Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc. Natt Acad Sci. USA, 99, 12483-12488.
6. Tiano,H.F., Loftin,C.D., Akunda,J. et al. (2002) Deficiency of either cyclooxygenase (COX)-l or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res., 62, 3395-3401.
7. Wilgus,T.A., Breza,T.S.Jr, Tober,K.L. and Oberyszyn,T.M. (2004) Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. J. Invest. Dertnatol., 122, 1488-1494.
8. Fischer,S.M., Conti,C.J., Viner,J., Aldaz,C.M. and Lubet,R.A. (2003) Celecoxib and difluoromethylomithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis, 24,945-952.
9. Pendand,A.P., Schoggins,J.W., Scott,G.A., Khan,K.N. and Han,R. (1999) Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis, 20, 1939-1944.
10. Muller-Decker,K., Kopp-Schneider,A., Marks,F., Seibert,K. and Furstenberger,G. (1998) Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol. Carcinog., 23, 36-44.
11. Fischer,S.M., Lo,H.H., Gordon,G.B., Seibert,K., Kelloff,G., Lubet,R.A. and Conti,C.J. (1999) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinog., 25, 231-240.
12. Keith,R.L., Miller,Y.E., Hoshikawa,Y., Moore,M.D., Gesell,T.L., Gao,B., Malkinson,A.M., Golpon,H.A., Nemenoff,R.A. and Geraci,M.W. (2002) Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res., 62, 734-740.
13. Keith,R.L., Miller,Y.E., Hudish,T.M., Girod,C.E., Sotto-Santiago,S., Franklin,W.A., NemenoffR.A., March,T.H., Nana-Sinkam,S.P. and Geraci,M.W. (2004) Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res., 64, 5897-5904.
14. Honn,K.V. and Meyer,J. (1981) Thromboxanes and prostacyclin: Positive and negative modulators of tumor growth. BiochenL Biophys. Res. Commun., 102, 1122-1129.
15. Schneider,M.R., Tang,D.G., Schimer,M. and Honn,K.V. (1994) Prostacyclin and its analogues: Antimetastatic effects and mechanisms of action. Cancer Metastasis Rev., 13, 349-364.
16. Bregman,M.D., Funk,C. and Fukushima,M. (1986) Inhibition of human melanoma growth by prostaglandin A, D, and J analogues. Cancer Res., 46,2740-2744.
17. Fukushima,M., Kato,T., Ueda,R., Ota,K., Narumiya,S. and Hayaishi,O. (1982) Prostaglandin D2, a potential antineoplastic agent. BiochenL Biophys. Res. Commun., 105,956-964.
18. Fukushima,S., Kishimoto,S., Takeuchi,Y. et al. (1998) [Pharmaceutical and pharmacological development of antitumor Prostaglandins.] (in Japanese). Nippon Rinsho, 56, 663-669.
19. Kikuchi,Y., Kita,T., Hirata,J., Kuki,E., Nagata,I. and Fukushima,M. (1992) Modulation of human lymphocyte response to phytohemagglutinin by antineoplastic prostaglandins. Int. J. Immunopharnwcol., 14, 105-110.
20. Kikuchi,Y., Kita,T., Miyauchi,M., Hirata,J., Sasa,H., Nagata,I. and Fukushima,M. (1992) Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells. J. Cancer Res. Clin. Oncol., 118, 453-457.
21. Narumiya,S. and Fukushima,M. (1986) Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone Prostaglandins, a reaction leading to growth inhibition. J. Pharmacol. Exp. Ther., 239, 500-505.
22. Narumiya,S. and Fukushima,M. (1987) Active transport and cellular accumulation of cyclopentenone prostaglandins: A mechanism of prostaglandin-induced growth inhibition. Adv Prostaglandin Thromboxane Leukot Res., 17B, 972-975.
23. Narumiya,S., Ohno,K., Fujiwara,M. and Fukushima,M. (1986) Site and mechanism of growth inhibition by prostaglandins. II. Temperature-dependent transfer of a cyclopentenone prostaglandin to nuclei. J. Pharmacol. Exp. Ther., 239, 506-511.
24. Sasaki,H. and Fukushima,M. (1994) Prostaglandins in the treatment of cancer. Anticancer Drugs, 5, 131-138.
25. Michalik,L., Desvergne,B. and Wahli,W. (2004) Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat. Rev. Cancer, 4, 61-70.
26. Yu,K., Bayona,W., Kallen,C.B., Harding,H.P., Ravera,C.P., McMahon,G., Brown,M. and Lazar,M.A. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem., 270, 23975-23983.
27. Forman,B.M., Chen,J. and Evans,R.M. (1997) Hypolipidemic drugs, poly-unsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl Acad Sci. USA, 94, 4312-4317.
28. Kliewer,S.A., Sundseth,S.S., Jones,S.A. et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl Acad Sci. USA, 94, 4318-4323.
29. DuBois,R.N., Gupta,R., Brockman,J., Reddy,B.S., Krakow,S.L. and Lazar,M.A. (1998) The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis, 19, 49-53.
30. Gupta,R.A., Tan,J., Krause,W.F., Geraci,M.W., Willson,J.M., Dey,S.K. and DuBois,R.N. (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl Acad Sci. USA, 97,13275-13280.
31. Gupta,R.A., Wang,D., Katkuri,S., Wang,H., Dey,S.K. and DuBois,R.N. (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat. Med., 10,245-247.
32. Harman,F.S., Nicol,C.J., Marin,H.E., Ward,J.M., Gonzalez,F.J. and Peters,J.M. (2004) Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat. Med., 10, 481-483.
33. Kim,D.J., Akiyama,T.E., Harman,F.S,, Burns,A.M., Shan,W., Ward,J.M., Kennett,M.J., Gonzalez,F.J. and Peters,J.M. (2004) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem., 279, 23719-23727.
34. Reed,K.R., Sansom,O.J., Hayes,A.J., Gescher,A.J., Winton,D.J., Peters,J.M. and Clarke,A.R. (2004) PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene, 23, 8992-8996.
35. Jove,M., Laguna,J.C. and Vazquez-Carrera,M. (2005) Agonist-induced activation releases peroxisome proliferator-activated receptor beta/ delta from its inhibition by palmitate-induced nuclear factor-kappaB in skeletal muscle cells. Biochim Biophys. Acta, 1734, 52-61.
36. Westergaard,M., Henningsen,J., Johansen,C. et al. (2003) Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J. Invest. Dermatol., 121, 1104-1117.
37. Shi,Y., Hon,M. and Evans,R.M. (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl Acad. Sci. USA, 99, 2613-2618.
38. Kim,D.J., Bility,M.T., Billin,A.N., Willson,T.M., Gonzalez,F.J. and Peters,J.M. (2006) PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death Differ., 13, 53-60.
39. Schmuth,M., Haqq,C.M., Cairns,W.J. et al. (2004) Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol., 122, 971-983.
40. Lee,C.H., Chawla,A., Urbiztondo,N., Liao,D., Boisvert,W.A., Evans,R.M. and Curtiss,L.K. (2003) Transcriptional repression of atherogenic inflammation: Modulation by PPARdelta. Science, 302, 453-457.
41. Peters,J.M., Lee,S.S.T., Li,W., Ward,J.M., Gavrilova,O., Everett,C., Reitman,M.L., Hudson,L.D. and Gonzalez,F.J. (2000) Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell Biol., 20,5119-5128.
42. Beazer-Barclay,Y., Levy,D.B., Moser,A.R., DoveW.F., Hamilton,S.R., Vogelstein,B. and Kinzler,K.W. (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis, 17, 1757-1760.
43. Chiu,C.H., McEntee,M.F. and Whelan,J. (1997) Sulindac causes rapid regression of preexisting tumors in Nfin/+ mice independent of prostaglandin biosynthesis. Cancer Res., 57, 4267-4273.
44. McEntee,M.F., Chiu,C.H. and Whelan,J. (1999) Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis, 20, 635-640.
45. Kim,D.J., Murray,I.A., Burns,A.M., Gonzalez,F.J., Perdew,G.H. and Peters,J.M. (2005) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem., 280, 9519-9527.
46. Subbaramaiah,K., Zakim,D., Weksler,B.B. and Dannenberg,A.J. (1997) Inhibition of cyclooxygenase: A novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med., 216, 201-210.
47. Konger,R.L., Scott,G.A., Landt,Y., Ladenson,J.H. and Pentland,A.P. (2002) Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression. Am. J. Pathol., 161, 2065-2078.
48. Mutoh,M., Watanabe,K., Kitamura,J. et at. (2002) Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res., 62, 28-32.
49. Seno,H., Oshima,M., Ishikawa,T.O., Oshima,H., Takaku,K., Chiba,T., Narumiya,S. and Taketo,M.M. (2002) Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta7l6) mouse intestinal polyps. Cancer Res., 62, 506-511.
50. Sonoshita,M., Takaku,K., Sasaki,N., Sugimoto,Y., Ushikubi,F., Narumiya,S., OshimaM. and Taketo,M.M. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Meil., 7, 1048-105 1.
51. Watanabe,K., Kawamori,T., Nakatsugi,S. et al. (1999) Role of the prostaglandin E receptor subtype EPI in colon carcinogenesis. Cancer Res., 59, 5093-5096.
52. Wang,D., Wang,H., Shi,Q., Katkuri,S., Walhi,W., Desvergne,B., Das,S.K., Dey,S.K. and DuBois,R.N. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell, 6, 285-295.
53. Lee,S.H., Williams,M.V., Dubois,R.N. and Blair,I.A. (2005) Cyclooxygenase-2-mediated DNA damage. J. Biol. Chem., 280, 28337-28346.
54. Marnett,L.J. (1981) Polycyclic aromatic hydrocarbon oxidation during prostagiandin biosynthesis. Life Sci., 29, 531-546.
55. Sivarajah,K., Anderson,M.W. and Eling,T.E. (1978) Metabolism of benzo(a)pyrene to reactive intermediate(s) via prostaglandin biosynthesis. Life Sci., 23, 2571-2578.
56. Smith,B.J., Curtis,J.F. and Eling,T.E. (1991) Bioactivation of xenobiotics by prostaglandin H synthase. Chem. Biol. Interact., 79, 245-264.
57. Kaneko,F., Zhang,J.Z., Maruyama,K., Nihei,Y., Ono,I., Iwatsuki,K. and Yamamoto,T. (1995) Prostaglandin I1 analogues, SM-10902 and SM-10906, affect human keratinocytes and fibroblasts in vitro in a manner similar to PGEl: Therapeutic potential for wound healing. Arch. Dermatol. Res., 287, 539-545.
58. Li,R.C., Cindrova-Davies,T., Skepper,J.N. and Sellers,L.A. (2004) Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated 3 inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ. Res., 94, 759-767.
59. Phillips,P.G., Long,L., Wilkins,M.R. and Morrell,N.W. (2005) cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am. J. Physiol. Lung Cell Mol. Physiol., 288, 1,103-1,115.
60. Fukumoto,K., Yano,Y., Virgona,N., Hagiwara,H., Sato,H., Senba,H., Suzuki,K., Asano,R., Yamada,K. and Yano,T. (2005) Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett., 579, 3829-3836.